Physician profile
Leslie Mills
NPI 1497000723
$3,275.30
in general payments reported to CMS, 2019-2025
26 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,680 · 2020: $755 · 2021: $654 · 2022: $28.33 · 2024: $27.58 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $387.60 | 2019-2025 | |
| Ucb, INC. | $335.61 | 2019-2021 | |
| Galderma Laboratories, L.P. | $307.97 | 2019-2025 | Nemluvio |
| Pfizer INC. | $261.98 | 2019-2021 | |
| Lilly USA, LLC | $230.71 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $226.89 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $186.16 | 2019-2020 | |
| Leo Pharma INC. | $150.22 | 2019-2021 | |
| Janssen Biotech, INC. | $148.25 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $117.65 | 2019-2021 | |
| Epi Health, LLC | $115.32 | 2019-2021 | |
| Aclaris Therapeutics, INC. | $110.33 | 2019 | |
| Celgene Corporation | $101.57 | 2019 | |
| Genentech USA, INC. | $99.34 | 2019-2021 | |
| Almirall LLC | $91.83 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $65.34 | 2019-2020 | |
| Amgen INC. | $60.54 | 2021 | |
| Incyte Corporation | $55.91 | 2022-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $51.64 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $36.43 | 2020-2021 | |
| Dermira, INC. | $36.35 | 2019-2020 | |
| Genzyme Corporation | $30.11 | 2020 | |
| Promius Pharma LLC | $28.03 | 2019 | |
| Mission Pharmacal Company | $15.00 | 2021 | |
| Dusa Pharmaceuticals, INC. | $12.95 | 2019 | |
| Merck Sharp & Dohme LLC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.